Wedbush Maintains Outperform on Albireo Pharma, Raises Price Target to $82
Wedbush analyst Liana Moussatos maintains Albireo Pharma (NASDAQ:ALBO) with a Outperform and raises the price target from $73 to $82.
HC Wainwright & Co. Maintains Buy on Albireo Pharma, Raises Price Target to $79
HC Wainwright & Co. analyst Ed Arce maintains Albireo Pharma (NASDAQ:ALBO) with a Buy and raises the price target from $76 to $79.
Albireo’s Rare Liver Disease Drug Bylvay Scores Back To Back Approvals In Europe, US
Just a day after European approval, Albireo Pharma Inc (NASDAQ:ALBO) has received FDA approval for Bylvay (odevixibat), the first drug approved to treat…
Albireo Pharma Issues PR Confirming FDA Approval For Co.’s Odevixibat
– Only once-daily drug indicated for the treatment of pruritus in PFIC –
– Commercial launch of Bylvay immediate; available for prescription in the coming days –
– Rare Pediatric
Albireo Pharma Shares Spike Higher As Traders Circulate FDA AccessData.gov Listing Showing FDA Approval For Co.’s Odevixibat
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215498
The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 19)
Albireo’s Bylvay Scores European Nod For Rare Pediatric Liver Disease
The European Commission (EC) has approved Albireo Pharma Inc’s (NASDAQ:ALBO) Bylvay (odevixibat) for all subtypes of progressive familial intrahepatic cholestasis (PFIC). …
The Week Ahead In Biotech: Earnings Kickstart With J&J And Biogen, Albireo Awaits FDA Decisions, More IPOs
Biotech stocks were down for a second week in a row, as they retreated along with the broader market amid macro concerns. Consumer price inflation data released during the week stoked rate hike fears, and exerted negative pressure on stocks.
There were very few stock-specific catalysts, barring a few preannouncements, stock offerings, and a slew of initial public offerings.
Attention Biotech Investors: Mark Your Calendar For July PDUFA Dates
June was a month of plenty and also turned out to be a fruitful one from the perspective of Food and Drug Administration approvals. Regulatory reviews mostly produced positive verdicts, and rejections or no-decisions were few and far between.
Albireo’s Bylvay Shows Further Evidence Of Sustained, Durable Effect In Pediatric Liver Disease Study
Albireo Pharma Inc (NASDAQ:ALBO) has announced pooled analysis from Phase 3 PEDFIC studies with Bylvay (odevixibat) and advancement in the characterization…